J&J settles COVID vaccine dispute with Emergent
J&J’s Janssen Pharmaceuticals entered an agreement with contract development and manufacturing organization (CDMO) Emergent BioSolutions in 2020 to produce its investigational SARS-CoV-2 vaccine, a viral vector recombinant based on J&J’s AdVac …